/VERA
VERA Stock - Vera Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$51.22+7.40%
+$3.53 (+7.40%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+51.5%upside
Target: $77.60
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VERA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$50.71 – $51.73
TARGET (TP)$77.60
STOP LOSS$47.12
RISK/REWARD1:6.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.21
52W High$51.72
52W Low$18.53
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | $846,000 | N/A | $-251,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-167,170,000 | $-102,012,000 | $-90,903,000 | $-34,402,000 | $-48,060,000 |
| Net Income | $-152,148,000 | $-95,990,000 | $-89,056,000 | $-32,609,000 | $-53,413,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.75 | $-2.25 | $-3.35 | $-2.43 | $-14.40 |
Company Overview
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
85%
Hold / Neutral
2
15%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
11 Bullish2 Neutral/Bearish
Price Targets
$37
Average Target
↓ 26.9% Downside
Now
$6
Low
$37
Average
$75
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 16th 2025 | BofA Securities | Initiation | Buy | $48 |
| August 4th 2025 | Wolfe Research | Downgrade | Peer Perform | - |
| May 5th 2025 | H.C. Wainwright | Resumed | Buy | $75 |
| February 4th 2025 | Wolfe Research | Initiation | Outperform | $49 |
| January 28th 2025 | Goldman | Initiation | Buy | $58 |
| November 21st 2024 | Wells Fargo | Initiation | Overweight | $70 |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| January 25th 2024 | Oppenheimer | Initiation | Outperform | $26 |
| January 8th 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| December 18th 2023 | Raymond James | Initiation | Outperform | $29 |
| November 10th 2023 | Jefferies | Upgrade | Buy | $26← $18 |
| August 16th 2023 | Guggenheim | Initiation | Buy | $27 |
| January 4th 2023 | Jefferies | Downgrade | Hold | $6← $32 |
| January 4th 2023 | Wedbush | Downgrade | Neutral | $8← $33 |
| July 12th 2022 | JP Morgan | Initiation | Overweight | $35 |
Earnings History & Surprises
VERABeat Rate
33%
Last 18 quarters
Avg Surprise
-6.9%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-1.26
Q4 2025
EPS Surprise History
Q1 24
-9.4%
$-0.58vs$-0.53
Q2 24
-5.7%
$-0.56vs$-0.53
Q3 24
-6.9%
$-0.62vs$-0.58
Q4 24
-23.2%
$-0.85vs$-0.69
Q1 25
+13.3%
$-0.72vs$-0.83
Q2 25
-8.0%
$-0.81vs$-0.75
Q3 25
-46.3%
$-1.20vs$-0.82
Q4 25
-5.0%
$-1.26vs$-1.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-1.36 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-1.20 | $-1.26 | -5.0% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.82 | $-1.20 | -46.3% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.75 | $-0.81 | -8.0% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.83 | $-0.72 | +13.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.69 | $-0.85 | -23.2% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.58 | $-0.62 | -6.9% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.53 | $-0.56 | -5.7% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $-0.53 | $-0.58 | -9.4% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.50 | $-0.45 | +10.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.69 | $-0.46 | +33.3% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.60 | $-0.80 | -33.3% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | $-0.93 | $-1.19 | -28.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.72 | $-0.91 | -26.4% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.72 | $-0.55 | +23.6% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.67 | $-0.71 | -6.0% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-0.49 | $-0.79 | -61.2% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.60 | $-0.36 | +40.0% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.39 | $-0.33 | +15.4% | ✓ BEAT |
Latest News
Vera Therapeutics shares are trading higher after multiple analyst firms raised their respective price targets on the stock.
📈 PositiveBenzinga•Dec 19, 2025, 06:14 PM
B of A Securities Maintains Buy on Vera Therapeutics, Raises Price Target to $66
📈 PositiveBenzinga•Dec 19, 2025, 05:52 PM
Goldman Sachs Maintains Buy on Vera Therapeutics, Raises Price Target to $95
📈 PositiveBenzinga•Dec 19, 2025, 05:12 PM
JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $96
➖ NeutralBenzinga•Dec 19, 2025, 04:31 PM
Wedbush Maintains Neutral on Vera Therapeutics, Raises Price Target to $33
➖ NeutralBenzinga•Dec 11, 2025, 02:27 PM
Vera Therapeutics shares are trading lower after the company announced plans to commence an offering to issue and sell $200 million shares of its Class A common stock.
📉 NegativeBenzinga•Dec 9, 2025, 02:00 PM
Vera Therapeutics shares are trading lower after the company announced plans to commence an offering to issue and sell $200 million shares of its Class A common stock.
📉 NegativeBenzinga•Dec 8, 2025, 09:25 PM
Vera Therapeutics Plans To Commence Public Offering To Issue And Sell $200M Of Shares Of Its Class A Common Stock
➖ NeutralBenzinga•Dec 8, 2025, 09:02 PM
Evercore ISI Group Maintains Outperform on Vera Therapeutics, Raises Price Target to $97
📈 PositiveBenzinga•Dec 8, 2025, 03:09 PM
TD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $73
📈 PositiveBenzinga•Dec 5, 2025, 05:11 PM
Vera Therapeutics shares are trading higher after the company announced its ORIGIN Phase 3 trial met its primary endpoint. HC Wainwright maintained a Buy rating on the stock and raised its price target from $85 to $90.
📈 PositiveBenzinga•Nov 10, 2025, 04:47 PM
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Raises Price Target to $90
📈 PositiveBenzinga•Nov 10, 2025, 11:57 AM
Reported Friday, Vera Therapeutics Submits BLA To FDA For Atacicept After ORIGIN Phase 3 Interim Analysis Demonstrates 42% Proteinuria Reduction Vs Placebo
📈 PositiveBenzinga•Nov 10, 2025, 09:40 AM
JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $52
➖ NeutralBenzinga•Nov 7, 2025, 08:31 PM
Vera Therapeutics Data From ORIGIN Phase 3 Study Of Atacicept In IgA Nephropathy Demonstrated 46% Reduction From Baseline In Proteinuria; Meets Secondary Endpoints
📈 PositiveBenzinga•Nov 6, 2025, 02:53 PM
Vera Therapeutics Q3 EPS $(1.26) Misses $(1.16) Estimate
📉 NegativeBenzinga•Nov 5, 2025, 12:30 PM
Reported Earlier: Vera Therapeutics To Present Phase 3 Atacicept Data For IgAN In Featured Late-Breaking Session At ASN Kidney Week 2025
📈 PositiveBenzinga•Oct 17, 2025, 03:31 PM
B of A Securities Initiates Coverage On Vera Therapeutics with Buy Rating, Announces Price Target of $48
📈 PositiveBenzinga•Oct 16, 2025, 11:47 AM
Vera plunges as Otsuka outperforms with IgA nephropathy therapy
📉 NegativeSeeking Alpha•Jun 6, 2025, 11:00 AM•Also:
Vera rises after success in late-stage trial for IgA nephropathy treatment
📈 PositiveSeeking Alpha•Jun 2, 2025, 05:07 PM
Frequently Asked Questions about VERA
What is VERA's current stock price?
Vera Therapeutics, Inc. (VERA) is currently trading at $51.22 per share. The stock has moved +7.40% today.
What is the analyst price target for VERA?
The average analyst price target for VERA is $77.60, based on 1 analyst.
What sector is Vera Therapeutics, Inc. in?
Vera Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VERA's market cap?
Vera Therapeutics, Inc. has a market capitalization of $3.27 billion, making it a mid-cap company.
Does VERA pay dividends?
No, Vera Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
HRMY
Harmony Biosciences Holdings, Inc.
$37.81
Mkt Cap: $2.2B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
QURE
uniQure N.V.
$23.99
Mkt Cap: $1.3B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to VERA for comparison